India Self-Monitoring Blood Glucose Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 140 Million |
| Market Size (2029) | USD 163 Million |
| CAGR (2024 - 2029) | 2.90 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
India Self-Monitoring Blood Glucose Devices Market Analysis
The India Self-Monitoring Blood Glucose Devices Market size is estimated at USD 140 million in 2024, and is expected to reach USD 163 million by 2029, growing at a CAGR of 2.9% during the forecast period (2024-2029).
Technological advancements in blood glucose meters, including cellular-connected devices that automatically upload SMBG data to secure cloud-based databases, allow for improved sharing and monitoring of SMBG data.
Real-time monitoring of SMBG data presents opportunities to provide timely support to patients who are responsive to abnormal SMBG recordings. Such advantages can provide patients with poorly controlled T2D with the additional support needed to improve critical outcomes, thereby enhancing the market's prospects in the years to come.
Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. The measurement of blood glucose helps in determining the effectiveness of blood glucose metabolism and guides in achieving optimal glucose control within the body.
Over time, the readings provide the patient and their health professionals with the information required to determine the best management strategy for diabetes. Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
India Self-Monitoring Blood Glucose Devices Market Trends
Rising Diabetes Prevalence in India
The diabetes population in India is expected to grow by about 1.9% over the forecast period.
According to IDF estimates, the number of people with diabetes in India was the second highest in the world, after China. One in 12 adults, or more than 74 million people living in India, are diabetes patients. A further 40 million adults in India have impaired glucose tolerance, which places them at high risk of developing type-2 diabetes. More than half of people living with diabetes in India are undiagnosed.
Nearly 10% of India's population is likely to be affected by diabetes over the forecast period. Obesity, especially central obesity, increased visceral fat due to physical inactivity, and consumption of high-calorie, high-fat, and high-sugar diets are the major contributing factors to diabetes in Indians. The most prominent work culture perpetuated in the country, which includes sitting for hours in one position and eating fast food with little or no physical activity, is a significant contributor to diabetes in the working-age group, causing this rapid increase in diabetes cases in India.
Various pieces of evidence suggest that diabetes can be successfully managed, especially when detected early. Multifactorial intervention, including control of blood glucose, blood pressure, and lipids, can reduce the broad range of diabetes-related microvascular and macrovascular complications and premature mortality.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Glucometer Devices Segment is expected to witness the highest CAGR over the forecast period
The glucometers segment is expected to register the highest CAGR of about 4.4% in the market over the forecast period owing to the increasing adoption of glucometers in home care settings, the growing preference for home-based self-monitoring, and recent product launches of advanced glucometers.
Glucose monitoring gives people living with diabetes a complete picture of their blood sugar levels, which can influence short- and long-term treatment decisions and improve health outcomes. It allows them and their healthcare providers to assess their glycemic status and adverse effects and to determine the effectiveness of glucose-lowering therapies. Glucose monitoring has the potential to improve blood sugar management and quality of life for people living with diabetes, resulting in physical, social, emotional, and functional benefits.
Capillary blood glucose monitoring, or self-monitoring of blood glucose, is one way for people living with diabetes to measure and assess their glucose levels. It uses a drop of blood from a finger prick to get a blood glucose reading using a blood glucose meter or glucometer. Those with diabetes are advised to work with their care team to determine the frequency and pattern of testing.
According to the Ministry of Health and Family Welfare of the Government of India, out of all deaths in India, 60% were related to non-communicable diseases like diabetes, cardiovascular diseases, cancer, chronic respiratory diseases, etc. To prevent and control major NCDs, the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) has been launched. This program includes medical education, health awareness in schools, and urban planning for diabetes.
Thus, the above-mentioned factors are expected to drive segment growth over the forecast period.
India Self-Monitoring Blood Glucose Devices Industry Overview
The Indian self-monitoring blood glucose device market is fragmented, with few significant and other generic players. Manufacturers like Abbott, LifeScan, F. Hoffmann-La Roche AG, Dr. Morepen, Ascensia, etc. occupy a major share.
India Self-Monitoring Blood Glucose Devices Market Leaders
-
Roche Diabetes Care
-
Abbott Diabetes Care
-
Ascensia Diabetes Care
-
LifeScan
-
Dr. Morepen
*Disclaimer: Major Players sorted in no particular order
India Self-Monitoring Blood Glucose Devices Market News
- May 2023: Roche Diabetes Care has collaborated with Sanmina-SCI India and Parekh Integrated Services for manufacturing and distribution of the blood glucose devices. The production of Accu-Chek Active metres will take place in Sanmina’s multi-client manufacturing site in Chennai, in line with globally approved quality standards, the company has said. The new Accu-Chek Active product packs will now display the ‘Made in India’ tag.
- March 2022: Zyla Health launched an integrated offering together with Accu-Chek, which provided the best of both worlds for a diabetes patient - a smart glucometer coupled with continuous diabetes care under leading doctors and experts that enables effectively managing diabetes. The offering was launched on Amazon & Flipkart & is now available for users across the country to benefit from.
India Self-Monitoring Blood Glucose Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Component
5.1.1 Glucometer Devices
5.1.2 Test Strips
5.1.3 Lancets
6. MARKET INDICATORS
6.1 Type-1 Diabetes population
6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche Diabetes Care
7.1.3 LifeScan
7.1.4 Dr. Morepen
7.1.5 Arkray Inc.
7.1.6 Ascensia Diabetes Care
7.1.7 Menarini
7.1.8 BeatO
7.1.9 Dr. Trust
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
India Self-Monitoring Blood Glucose Devices Industry Segmentation
Self-monitoring of blood glucose is an approach used by diabetic patients to measure their blood sugar level themselves using a glucometer, test strips, and lancets. Based on the readings, patients can adjust or check the effect of their treatment. The India self-monitoring blood glucose device market is segmented by components. The report offers the value (in USD) and volume (in units) for the above segments.
| Component | |
| Glucometer Devices | |
| Test Strips | |
| Lancets |
India Self-Monitoring Blood Glucose Devices Market Research Faqs
How big is the India Self-Monitoring Blood Glucose Devices Market?
The India Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 140 million in 2024 and grow at a CAGR of 2.9% to reach USD 163 million by 2029.
What is the current India Self-Monitoring Blood Glucose Devices Market size?
In 2024, the India Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 140 million.
Who are the key players in India Self-Monitoring Blood Glucose Devices Market?
Roche Diabetes Care, Abbott Diabetes Care, Ascensia Diabetes Care, LifeScan and Dr. Morepen are the major companies operating in the India Self-Monitoring Blood Glucose Devices Market.
What years does this India Self-Monitoring Blood Glucose Devices Market cover, and what was the market size in 2023?
In 2023, the India Self-Monitoring Blood Glucose Devices Market size was estimated at USD 135.94 million. The report covers the India Self-Monitoring Blood Glucose Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the India Self-Monitoring Blood Glucose Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
India Self-Monitoring Blood Glucose Devices Industry Report
Statistics for the 2024 India Self-Monitoring Blood Glucose Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Self-Monitoring Blood Glucose Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
